Infertility

Renowned Los Angeles Urologist Dr. Justin Houman Appointed Assistant Professor at Cedars-Sinai Medical Center

Retrieved on: 
Wednesday, March 20, 2024
Diagnosis, Peyronie's disease, Health, Infertility, Prostate cancer, Assistant, Knowledge, Research, Fertility, Patient, Suite, Male, Cedars-Sinai Medical Center, Publication, Urinary tract infection, Erectile dysfunction, LOS, Kidney, Assistant professor

LOS ANGELES, March 20, 2024 /PRNewswire-PRWeb/ -- Cedars-Sinai Medical Center proudly announces the appointment of Dr. Justin Houman, a distinguished Los Angeles-based urologist, as Assistant Professor in the esteemed Department of Urology. With a wealth of experience in clinical practice, research, and medical education, Dr. Houman's appointment marks a significant addition to Cedars-Sinai's renowned team.

Key Points: 
  • Dr. Justin Houman, M.D., brings expertise in clinical care, research, and medical education to Cedars-Sinai's Department of Urology.
  • LOS ANGELES, March 20, 2024 /PRNewswire-PRWeb/ -- Cedars-Sinai Medical Center proudly announces the appointment of Dr. Justin Houman, a distinguished Los Angeles-based urologist , as Assistant Professor in the esteemed Department of Urology.
  • With a wealth of experience in clinical practice, research, and medical education, Dr. Houman's appointment marks a significant addition to Cedars-Sinai's renowned team.
  • In his role as Assistant Professor, Dr. Houman will impart invaluable knowledge and mentorship to medical students, residents, and fellows in urology.

Imaging with [99m]Tc-Maraciclatide Correlates with Identification of Early-Stage Endometriosis by Laparoscopic Surgery

Retrieved on: 
Friday, March 15, 2024
Diagnosis, Uncertainty, Histology, Growth, Infertility, Cyst, Disease, University, Pelvis, Endometrioma, Patient, Rectum, Abdomen, Laparoscopy, Endometriosis, Society, Integrin, Woman, SRI, Pain, University of Oxford, FDA, Medical imaging

The imaging findings were compared to the surgical and histology reports and indicate that 99mTc-maraciclatide holds potential as a non-invasive test for early-stage endometriosis.

Key Points: 
  • The imaging findings were compared to the surgical and histology reports and indicate that 99mTc-maraciclatide holds potential as a non-invasive test for early-stage endometriosis.
  • Professor Christian Becker, Co-Director of the Endometriosis CaRe Centre in Oxford added: "Endometriosis is a common disease affecting many millions of women worldwide with pain and infertility.
  • Therefore, a novel imaging tool to assist healthcare professionals in identifying or ruling out the disease is urgently needed."
  • At the Endometriosis CaRe Centre at the University of Oxford our studies focus on identifying novel genetic, diagnostic and therapeutic targets for endometriosis.

Alife Health Partners with Boston IVF on AI Technology for IVF Treatment Optimization

Retrieved on: 
Tuesday, March 12, 2024
Algorithm, Infertility, Stim, Partnership, SAN, Patient, IVF, Research, AI, Machine learning, Reproductive medicine, Medical device

SAN FRANCISCO and BOSTON, March 12, 2024 /PRNewswire/ -- Alife Health ("Alife"), a leading fertility technology company specializing in the development of AI tools for in vitro fertilization (IVF), has announced a groundbreaking partnership with Boston IVF, a leading fertility clinic with more than 25 locations across the U.S., to pilot the country's first AI tool for IVF medication optimization. Boston IVF will implement Alife's Stim Assist software, which is designed to help IVF clinicians retrieve the optimal number of eggs for each patient and reduce overall medication costs.

Key Points: 
  • SAN FRANCISCO and BOSTON, March 12, 2024 /PRNewswire/ -- Alife Health ("Alife"), a leading fertility technology company specializing in the development of AI tools for in vitro fertilization (IVF), has announced a groundbreaking partnership with Boston IVF , a leading fertility clinic with more than 25 locations across the U.S., to pilot the country's first AI tool for IVF medication optimization.
  • Boston IVF will implement Alife's Stim Assist software, which is designed to help IVF clinicians retrieve the optimal number of eggs for each patient and reduce overall medication costs.
  • The collaboration aims to advance the field of reproductive medicine by combining Alife's state-of-the-art AI technology with the expertise of Boston IVF's world-renowned fertility specialists.
  • "Our partnership with Alife marks a major milestone in the advancement of AI technology for fertility treatment," says David Stern, CEO of Boston IVF.

Paralyzed Veterans of America issues statement in response to VA's expansion of IVF

Retrieved on: 
Monday, March 11, 2024
PVA, Disability, Fertilisation, IVF, Family, Congress, Marital status, Infertility, Birth control

WASHINGTON, March 11, 2024 /PRNewswire/ -- Paralyzed Veterans of America Chief Executive Officer Carl Blake issues the following statement in response to the Department of Veterans Affairs' expansion of in vitro fertilization for disabled veterans seeking to grow their families.

Key Points: 
  • WASHINGTON, March 11, 2024 /PRNewswire/ -- Paralyzed Veterans of America Chief Executive Officer Carl Blake issues the following statement in response to the Department of Veterans Affairs' expansion of in vitro fertilization for disabled veterans seeking to grow their families.
  • "PVA has long supported increased access to assisted reproductive technologies, including in vitro fertilization, through VA for catastrophically disabled veterans to grow their families.
  • Blake continued, "While VA's announcement is a tremendous step forward, more advancements are still needed.
  • PVA has long called on Congress to authorize VA to provide assisted reproductive technology, including IVF, surrogacy, and gamete donation at VA for any veterans enrolled in VA health care.

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Retrieved on: 
Wednesday, March 6, 2024
FDA, ICSI, IVF, Supreme Court of Alabama, Woman, Infertility, Female, Fertilisation, Patient, Tubing (recreation)

ATLANTA, March 06, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces the first commercial procedure using its FemaSeed intratubal insemination product.

Key Points: 
  • “FemaSeed presents an important advancement in women’s health with the availability of FemaSeed, a cost-effective and potentially safer alternative to other traditional infertility treatments,” said Femasys’ CEO Kathy Lee-Sepsick.
  • “This first commercial application of the technology marks a pivotal moment in reshaping female infertility management, particularly in light of the recent legal rulings on frozen embryos by the Alabama Supreme Court.
  • Engineered to precisely deliver sperm into the fallopian tube, the site of conception, FemaSeed enables reliable and safe fertilization.
  • Dr. Andrew Wagner, Women’s OB-GYN PC, Saginaw, Michigan, who completed the first in-office commercial procedure, stated, “This marks a pivotal moment for women pursuing a reliable, readily available frontline alternative for infertility.

Hope for Women: Womed Unveils First Fertility Restoration Device Proven Effective in Randomized Clinical Trial

Retrieved on: 
Thursday, March 7, 2024
Research, Medical Devices, Women, Baby, Maternity, Clinical Trials, Health Technology, Biotechnology, Consumer, Health, Science, Hospital, Choix, Woman, Recurrence, Vaginal discharge, Multimedia, News, Uterus, Pain, Female, Safety, Obstetrics, Patient, Knowledge, Curettage, Infertility, IUA, Birth control

No device indicated for IUA prevention has been shown to be effective in this specific patient group.

Key Points: 
  • No device indicated for IUA prevention has been shown to be effective in this specific patient group.
  • PREG2 is an international, randomized clinical trial designed to measure Womed Leaf's effectiveness.
  • 160 women with severe or moderate IUA were randomly assigned to receive a Womed Leaf or not after adhesiolysis surgery.
  • "Womed Leaf, which is already registered in Europe and Brazil, will be marketed through commercial partners."

San Diego Fertility Center, an Ivy Fertility Clinic, Hires Dr. Valerie Flores

Retrieved on: 
Wednesday, February 21, 2024
Research, Women, Baby, Maternity, Practice Management, Family, Biotechnology, General Health, Consumer, Health, Science, Fertility preservation, MD, NIH, Physician, Pain, Endometriosis, University of Southern California, Yale University, University, SDFC, PCOS, Patient, Uterus, Brown, Infertility, Medical device

Ivy Fertility, a collaborative network of globally-renowned fertility clinics, has welcomed Valerie Flores, MD to its team of physicians at San Diego Fertility Center (SDFC).

Key Points: 
  • Ivy Fertility, a collaborative network of globally-renowned fertility clinics, has welcomed Valerie Flores, MD to its team of physicians at San Diego Fertility Center (SDFC).
  • “We are thrilled that Dr. Flores will be contributing her talents to our physician team,” said Sandy Chuan, MD, medical director at San Diego Fertility Center.
  • She comes to San Diego Fertility Center from Reproductive Partners Fertility Center in San Diego, is an Assistant Professor Adjunct at Yale University’s School of Medicine.
  • “I admire San Diego Fertility Center and Ivy Fertility for leading our industry by putting compassion and collaboration first,” said Dr. Flores.

JOURNALIST AND INFERTILE AF PODCAST HOST ALI PRATO WRITES CHILDREN'S BOOK ABOUT IVF, "WORK OF ART" - OUT TODAY

Retrieved on: 
Tuesday, March 5, 2024
Love, NBA, Basketball, Assisted reproductive technology, IVF, Fertility, INFO, ART, Infertility, Family, Child, Science, HERE, Birth control

MAPLEWOOD, N.J., March 5, 2024 /PRNewswire/ -- Ali Prato, journalist, Fertility Rally co-founder and Infertile AF podcast host, has written a groundbreaking children's book about IVF and family building through Assisted Reproductive Technology (ART), published today. 

Key Points: 
  • Ali Prato, host of Infertile AF podcast wrote a children's book about IVF and Assisted Reproductive Technology out now.
  • Ali is an infertility warrior and advocate who went through secondary infertility before having her second child, Sonny, through IVF.
  • Ali's podcast, Infertile AF, founded in 2019, has released more than 260 episodes and has been downloaded globally more than 1.4 million times.
  • But there's something about Sonny that sets him apart from the other kids – he was conceived through Assisted Reproductive Technology (ART) and IVF.

Illume Fertility Joins Senator Richard Blumenthal in News Conference Urging Congress to Pass Federal Protections for Infertility Treatment

Retrieved on: 
Tuesday, March 5, 2024
ASRM, Medicine, Reproductive medicine, Medical director, Fertility, IVF, Access, D-CT, Society, Partner, Supreme Court of Alabama, Fertilisation, Family, Patient, Legislation, Congress, Child, Reproductive rights, Infertility, Birth control

NORWALK, Conn., March 5, 2024 /PRNewswire-PRWeb/ -- Illume Fertility, a leading modern fertility practice with locations in Connecticut and New York, appeared alongside U.S. Sen. Richard Blumenthal (D-CT) and other reproductive rights advocates at a press conference in Hartford on Friday to demand federal protections for infertility treatments in the wake of the recent Alabama Supreme Court ruling restricting in vitro fertilization (IVF).

Key Points: 
  • "1 in 6 people worldwide suffer from infertility, and access to treatment options like IVF is essential.
  • My own family would not exist without IVF - for me and the millions of other Americans that need access to fertility care, this is personal."
  • Senator Blumenthal is calling on Congress to quickly pass the Access to Family Building Act, a bill introduced by Senator Tammy Duckworth (D-IL) which would override state limits and establish a statutory right to access in vitro fertilization (IVF) nationwide.
  • The Access to Family Building Act is endorsed by the American Society for Reproductive Medicine (ASRM) and RESOLVE: The National Infertility Association.

Government of Canada releases 2024-2030 Action Plan on Sexually Transmitted and Blood-Borne Infections

Retrieved on: 
Tuesday, February 27, 2024
Inhalation, Violence, Infection, Syphilis, CIHR, AIDS, Federation, Government, Action plan, Metis, Ectopic pregnancy, Viral hepatitis, First Nations, Science, Risk, Housing, Public, Research, Infertility, Cancer, Birth control

OTTAWA, ON, Feb. 27, 2024 /CNW/ - Sexually transmitted and blood-borne infections (STBBI) are largely preventable, treatable, and in many cases curable.

Key Points: 
  • OTTAWA, ON, Feb. 27, 2024 /CNW/ - Sexually transmitted and blood-borne infections (STBBI) are largely preventable, treatable, and in many cases curable.
  • However, rates of sexually transmitted infections in Canada have increased over the last decade—gonorrhea rates have doubled since 2012, and syphilis rates are five times what they were.
  • That is why today, the Honourable Mark Holland, Minister of Health, launched the Government of Canada's sexually transmitted and blood-borne infections (STBBI) action plan 2024-2030 and announced $2.45 million in funding to address STBBI in Canada.
  • The Action Plan will continue to work towards reducing STBBI related stigma, to prevent new and reoccurring infections and connect people to testing, prevention, treatment and care."